

**From:** Gruda Maryann <mgruda@kimeragen.com>  
**To:** "Sattar Lodhi, Ph.D." <asl@nrc.gov>  
**Date:** Mon, Jun 12, 2000 12:50 PM  
**Subject:** Kimeragen License Amendment

Dr. Lodhi,

I wish to update you on the status of Kimeragen since our telephone conversation on April 3rd concerning the merger of Kimeragen with ValiGene. After review of our merger conditions and management plan our lawyer, Lisa Malseed, has agreed that there is not a change of control of our license (license #37-30363-01) as per NUREG1556v15. However, after considerable discussion it has been decided that Kimeragen will change its name, most likely to: ValiGen (US), Inc. It is our intention to formally notify the NRC and amend our license as soon as a final decision on the name is reached.

Sincerely,

Maryann Gruda, Ph.D.

RSO

Kimeragen, Inc.

300 Pheasant Run

Newtown, PA 18940

215-504-4444 x122

*NUREG-002*